With over 20 CGTs projected to be approved by 2025, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth, unstable infrastructure, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization.
To realize this potential, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further, transforming our healthcare system to guarantee scalable and sustainable growth.
Don’t get left behind.
Join us at Reuters Events: Cell and Gene Therapy USA (September 20-21, virtual) where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers, 20+ interactive sessions and over 1500+ fellow CGT attendees - we will pioneer a new gold standard for commercialization, readying the world for CGT as a frontline treatment.
Manage unprecedented post-launch demand to ensure patient satisfaction: Analyse nuances in delivery model variations, such as in-house vs CMO’s and allogeneic vs autologous, to ensure your supply chain reflects the bespoke nature of precision medicine and accommodate the ability to adapt to market demand.
Now more than ever, we need to work together to effectively commercialize these incredible treatments for our customers and patients. Participate as a team of internal and external stakeholders to catch every drop of insight, make the most of networking and interactive sessions and unite to transform culture
Chief Commercial Officer
Chief Development Officer
Chief Medical Officer
Chief Operations Officer & Executive Vice President
Chief Technical Officer
Business Partner, Cell Therapy IT Head
Senior Vice President, Americas
Senior Vice President, Commercial Strategy & Capabilities
Vice President, Market Access
Vice President Patient Access
Vice President, Global Supply Chain
Vice President, Primary Focus Lead
Senior Director Corporate Strategy and Commercialization
Senior Director Trade & Distribution
Senior Director, Cell therapy Late-Stage CMC
Senior Director, Market Access
Director Tech Services - Supply Chain Integration
Director, Supply Chain
Director - Global Commercial Gene Therapy
Associate Director, IT for Commercialization
Solid Tumors Franchise Head
Head of Commercial Supply Chain | Cell & Gene Therapy
Business Technology Leader, Oncology & Cell Therapy
